论文部分内容阅读
目的:探索及分析急性脑梗死患者给予中风一号与纤溶酶联合用药方案进行治疗的临床效果。方法:收集新洲中医医院神经内科2015年1月至2016年10月接收的急性脑梗死患者60例,随机分成两组:对照组共30例,武汉市新洲中医医院行常规临床治疗;治疗组共30例,在对照组的治疗基础上加用中风一号与纤溶酶联合用药治疗。治疗后对两组患者的用药后的疗效进行评估分析,观察患者的神经功能缺损评分与血液流变学变化。结果:治疗组的总有效率较对照组患者显著更高,差异具有统计学意义(P<0.05);治疗组治疗后的神经功能缺损评分与各项血液流变学指标较治疗前、对照组均显著改善,差异具有统计学意义(P<0.05)。结论:急性脑梗死患者行中风一号与纤溶酶联合用药方案治疗疗效显著,值得临床借鉴。
Objective: To explore and analyze the clinical effect of treating patients with acute cerebral infarction with the combination of stroke No.1 and plasmin. Methods: Sixty patients with acute cerebral infarction received from January 2015 to October 2016 in Xinzhou Hospital of Traditional Chinese Medicine were randomly divided into two groups: control group, 30 cases, Wuhan Xinzhou Chinese Medicine Hospital routine clinical treatment; treatment A total of 30 cases in the control group based on the treatment of stroke plus plasmin combination therapy. After treatment, the therapeutic effect of the two groups of patients was evaluated and evaluated, and the neurological deficit scores and hemorheological changes of the patients were observed. Results: The total effective rate of the treatment group was significantly higher than that of the control group, the difference was statistically significant (P <0.05); after treatment, the neurological deficit score and the indexes of hemorheology were higher in the treatment group than in the control group Were significantly improved, the difference was statistically significant (P <0.05). Conclusion: The treatment of acute stroke patients with stroke No.1 and plasmin is effective and worthy of clinical reference.